Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 8/20 | 0.36 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198764 | 0.84 | MEN1 (0.37) | EPHX2HDAC1HDAC2HDAC6CTSK | |
| SCHEMBL28706088 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL20450540 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL30661131 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL2380206 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL14482131 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL3251209 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL14482719 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL3914424 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL28924668 | 0.84 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-5245047-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | HMGCR, DHCR7, LIPA | EPHX2 832/4885HDAC1 2988/4885HDAC2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.